Policy | February 22, 2023
Mandaviya focuses on high value pharmaceuticals and high-end medical devices to reduce the import dependency
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
Subscribe To Our Newsletter & Stay Updated
